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211Coronary Microvascular Dysfunction,
Microvascular Angina, and Treatment
StrategiesABSTRACTAngina without coronary artery disease (CAD) has substantial morbidity and is present in 10% to 30% of patients under-
going angiography. Coronary microvascular dysfunction (CMD) is present in 50% to 65% of these patients. The optimal
treatment of this cohort is undeﬁned. We performed a systematic review to evaluate treatment strategies for objectively-
deﬁned CMD in the absence of CAD.We included studies assessing therapy in human subjectswith angina and coronaryﬂow
reserve or myocardial perfusion reserve <2.5 by positron emission tomography, cardiac magnetic resonance imaging,
dilution methods, or intracoronary Doppler in the absence of coronary artery stenosis $50% or structural heart disease.
Only 8 papers met the strict inclusion criteria. The papers were heterogeneous, using different treatments, endpoints, and
deﬁnitions of CMD. The small sample sizes severely limit the power of these studies, with an average of 11 patients per
analysis. Studies evaluating sildenaﬁl, quinapril, estrogen, and transcutaneous electrical nerve stimulation application
demonstrated beneﬁts in their respective endpoints. No beneﬁt was found with L-arginine, doxazosin, pravastatin, and
diltiazem. Our systematic review highlights that there is little data to support therapies for CMD. We assess the data
meeting rigorous inclusion criteria and review the related but excluded published data. We additionally describe the next
steps needed to address this research gap, including a standardized deﬁnition of CMD, routine assessment of CMD in studies
of chest pain without obstructive CAD, and speciﬁc therapy assessment in the population with conﬁrmed CMD. (J Am Coll
Cardiol Img 2015;8:210–20) © 2015 by the American College of Cardiology Foundation.P atients with chest pain without obstructivecoronary artery disease (CAD) have been adiagnostic and therapeutic challenge and
have contributed to signiﬁcant economic, social,
and health care costs (1,2). At least 10% to 30% of pa-
tients presenting with angina have no signiﬁcant
CAD on invasive coronary angiography (3,4). As
many as 50% to 65% of these patients with chest
pain without obstructive CAD are believed to have
coronary microvascular dysfunction (CMD), also
known as microvascular angina (5–8). CMD is typi-
cally deﬁned as impaired vasodilation of arterioles,
leading to an inadequate increase in blood ﬂow
from rest to stress.
Patients believed to have CMD have a poor prog-
nosis, with higher rates of hospitalization and
increased rates of adverse cardiovascular events,
including sudden cardiac death, myocardial infarc-
tion, congestive heart failure, and coronary revascu-
larization (2,8–11).
Historically, the only practical methods available
for the assessment of CMD have been invasive, such
as intracoronary (IC) Doppler ﬂow wire or thermodi-
lution. This has likely impaired the objective evalua-
tion of CMD in patients presenting with chest pain
without obstructive CAD. Thus, the treatment of
CMD has often been studied within imprecise clinical
entities such as cardiac syndrome X (12). Moreover, alack of consensus on diagnostic criteria and nomen-
clature for CMD has further obscured the evidence
that sought to objectively deﬁne microvascular
angina as a distinct clinical entity.
Given these challenges, it is unclear to what
extent effective therapies have been identiﬁed in
patients with CMD. Therefore, we performed a
systematic review of the published data to evaluate
treatment strategies for CMD using a rigorous
deﬁnition with contemporary and accurate methods
of microvascular assessment. We found little data
that met these criteria. Accordingly, we analyze
the challenges in studying therapies for CMD,
present the results of our systematic review, discuss
the excluded but related published data, and
propose future research directions for this impor-
tant ﬁeld.
CURRENT CHALLENGES IN
CMD TREATMENT RESEARCH
CMD VERSUS OTHER CAUSES OF CHEST PAIN
WITHOUT OBSTRUCTIVE CAD. There are multiple
diagnoses that may cause chest pain without
obstructive CAD. These diagnoses include microvas-
cular angina, gastroesophageal reﬂux disease,
musculoskeletal chest pain, cardiac syndrome X,
cardiac syndrome Y (slow coronary ﬂow), coronary
FIGURE 1 Etiologies of Chest
The varying pathophysiologic m
artery disease (CAD) are grouped
cardiac nonischemic. The contrib
syndrome X is highlighted. Micro
as shown, but it has a narrower
ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
CBF = coronary blood ﬂow
CFR = coronary ﬂow reserve
CMD = coronary microvascular
dysfunction
CMR = cardiac magnetic
resonance imaging
EECP = enhanced external
counterpulsation
MPR = myocardial perfusion
reserve
PET = positron emission
tomography
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212spasm, and no reﬂow phenomena, among
others. These entities derive from multiple
different pathophysiological processes.
These various pathophysiological causes can
be described as causing noncardiac pain,
cardiac ischemic pain, and cardiac non-
ischemic pain (13). Among the causes of car-
diac ischemic chest pain in patients without
obstructive CAD, CMD is likely common.
However, the causes of CMD can be hetero-
geneous, and their relative contributions to
pathologic microvascular angina are poorly
understood. Among the leading contenders
are endothelial and smooth muscle dysfunc-
tion, inappropriate sympathetic tone, andmicrovascular atherosclerosis and inﬂammation (14)
(Figure 1).
Cardiac syndrome X is a well-known clinical entity
that is often used as an inclusion criterion in treat-
ment studies of patients with chest pain without CAD.
Cardiac syndrome X most often pertains to women
with angina, normal coronary arteries, and often ev-
idence of ischemia, such as abnormal electrocardio-
graphic ﬁndings or a positive nuclear stress test;Pain Without Obstructive CAD
echanisms of chest pain without obstructive coronary
into 3 broad categories: noncardiac; cardiac ischemic; and
ution of multiple potential pathophysiologies to cardiac
vascular angina overlaps partially with cardiac syndrome X
pathophysiological basis that is cardiac ischemic in nature.however, there is no standard deﬁnition for this en-
tity (15). There are numerous pathophysiological
causes for chest pain in patients with cardiac syn-
drome X that likely range from noncardiac to CMD
(16,17). Alternatively, microvascular angina is an
identiﬁable pathophysiological mechanism and
should be treated as a unique clinical entity (18,19)
(Figure 1).
CMD DIAGNOSTIC CRITERIA. There has been signif-
icant variation in the diagnostic criteria used to
deﬁne CMD. The current gold standards for clinically
assessing microvascular function have been coronary
ﬂow reserve (CFR) using invasive testing and
myocardial perfusion reserve (MPR) using positron
emission tomography (PET) or cardiac magnetic
resonance imaging (CMR) analysis. These values have
gained acceptance in part due to the applicability of
CFR or MPR across disparate diagnostic techniques
(20).
Even when CFR or MPR has been used as the pri-
mary diagnostic criterion for CMD, the threshold for
deﬁning dysfunction has differed between studies.
The current published data suggests that CFR and
MPR are continuous variables, and thus, any cutoff
used will have varying speciﬁcities and sensitivities.
Several important prognostic studies have used
thresholds of 1.5 to 2.3 to deﬁne cutoff values based
on prognostic data (2,8). However, many treatment
studies have included subjects with CFR or MPR
values >3 in their analysis. This has likely resulted in
a study population with disparate pathophysiologic
mechanisms that may respond differently to treat-
ment modalities.
In our systematic review, we have opted to maxi-
mize the sensitivity of our study by using the most
liberalized cutoff for which there is supportive prog-
nostic data among different diagnostic techniques. A
CFR cutoff of <2.5 had been proposed more than 20
years ago in patients undergoing PET assessment of
the microvasculature (6). Since then, it has been used
in various other prognostic studies in both patients
with and without CAD (21,22).
TECHNIQUES FOR CMD ASSESSMENT. Multiple
techniques have been used to assess microvascular
function. We considered PET, CMR, IC Doppler ﬂow
wire, and various dilution techniques as validated
methods for inclusion. Dilution techniques use tem-
perature gradient between the coronary arteries and
the coronary sinus to estimate blood ﬂow (23).
Doppler tipped wires measure intracoronary blood
velocity and arterial cross-sectional area to give an
estimate of ﬂow. Although these methods have
proven to be safe and effective (24), the advent of
FIGURE 2 Study Design Flow Diagram
The search strategy for our systematic review is detailed. From
the 285,399 subjects identiﬁed in an initial keyword search, only
8 papers met our strict inclusion criteria. The number of papers
excluded and their reasons for exclusion are detailed.
TABLE 1 Accepted Studies and Results
Treatment
Patients
(n)
Mean CFR or
MPR Baseline
Mean CFR
or MPR
With Therapy
Tr
D
ACE inhibitors
Quinapril 13 2.2  0.3 2.7  0.5 4 mon
Statins
Pravastatin 6 0.97 N/A 6 mon
Nitric oxide inhibitors
L-arginine infusion 12 2.0  0.5 N/A 1-time
Sildenaﬁl 12 2.1  0.2 2.7  0.6 1-time
Calcium-channel blockers
Diltiazem infusion 5 1.2  0.1 1.3  0.2 1-time
Estrogens
Norethindrone/ethinyl
estradiol
18 <2.25 N/A 12 wee
Alpha-blockers
Doxazosin 10 1.84  0.55 NA 10 wee
Other
TENS 8 1.59  0.15 1.90  0.1 4 week
Review of the different studies that have met our strict inclusion criteria for coronary m
CFR ¼ coronary ﬂow reserve; IC ¼ intracoronary; MPR ¼ myocardial perfusion reserv
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213noninvasive techniques such as PET and CMR increase
the feasibility of diagnosing CMD while removing the
risk associated with catheter based techniques.
PET perfusion imaging has become the gold
standard of evaluation due to the linear relationship
between myocardial blood ﬂow (MBF) and radioiso-
tope signal intensity, allowing highly accurate MBF
quantiﬁcation (25,26). The most commonly used
tracers are 13NH3, 82Rb, and 15O. MPR determination
by these tracers can vary signiﬁcantly based on
characteristics such as ﬁrst-pass extraction fraction,
positron range, and half-life. Even when using the
same tracer, the choice of methods for input func-
tion and myocardial extraction estimation can
signiﬁcantly affect the MPR value obtained for a
patient (27).
CMR offers potential advantages over PET, such as
superior temporal and spatial resolution, lack of
ionizing radiation, and wider scanner availability.
Semiquantitative upslope analysis was initially used,
but it underestimates MPR due to differences in
arterial contrast distribution, extracellular exchange,
and incomplete and varying ﬁrst-pass extraction (28).
However, robust fully-quantitative tracer kinetic
models using Fermi-deconvolution have been devel-
oped and validated (29–32). Lengthy ofﬂine post-
processing and other technical issues have limited
the application of CMR for CMD assessment to a few
experienced centers (33,34). Multiple analyses using a
variety of quantiﬁcation methods have shown goodeatment
uration
Mode of Assessing
CFR or MPR Findings First Author, Year (Ref. #)
ths IC Doppler Improvement in angina and CFR Pauly et al., 2011 (41)
ths IC Doppler No improvement in CFR Houghton et al., 2000 (49)
infusion PET scan No improvement in MPR Bøttcher et al., 1999 (56)
administration IC Doppler Improvement in CFR Denardo et al., 2011 (55)
infusion Thermodilution No improvement in CFR Sutsch et al., 1995 (46)
ks IC Doppler Improvement in angina Bairey Merz et al., 2010 (62)
ks Thermodilution No improvement in symptoms Bøtker et al., 1998 (60)
s PET scan Improvement in angina and MPR Jessurun et al., 2003 (64)
icrovascular dysfunction in patients with angina and no obstructive epicardial coronary artery disease.
e; PET ¼ positron emission tomography; TENS ¼ transcutaneous electrical nerve stimulation.
TABLE 2 Studies Not Meeting Inclusion Criteria but With Assessments of Microvascular Function
Treatment
Baseline
CFR <2.5
No CAD $50%
Stenosis
Mode of
Assessing
CFR or MPR Patients (n) Findings First Author, Year (Ref. #)
Renin/angiotensin/aldosterone inhibitors
Eplerenone 25 mg No Yes IC Doppler 25 Angina4, CFR4 Bavry et al., 2014 (44)
Candesartan 4–8 mg NA No IC Doppler 14 CFR [ Iino et al., 2012 (74)
Enalapril 5 mg 2 daily No Yes IC Doppler 10 Angina [, CFR [ Chen et al., 2002 (75)
Enalapril 10–20 mg/day No Yes Argon dilution 15 Symptoms [, CFR [ Motz et al., 1996 (43)
Enalapril 5 mg 2 daily No Yes PET 10 Exercise capacity [ Kaski et al., 1994 (42)
Statins
Fluvastatin 40 mg Yes Yes TTDE 23 Angina [, CFR [ Zhang et al., 2014 (50)
Atorvastatin 80 mg No No IC Doppler 20 CFR4 Eshtehardi et al., 2012 (51)
Atorvastatin 20 mg Yes Yes TTDE 20 CFR [ Caliskan et al., 2007 (52)
Nitric oxide modulators
L-arginine 1-time infusion No Yes IC Doppler 11 CBF Y Gellman et al., 2004 (58)
Tetrahydrobiopterin 1-time infusion No No IC Doppler 23 CBF [ Setoguchi et al., 2001 (76)
L-arginine infusion 3 g 3 daily No No IC Doppler 13 Angina [, CFR4 Lerman et al., 1998 (59)
L-arginine 1-time infusion No No IC Doppler 8 CBF [ Egashira et al., 1996 (57)
Calcium-channel blockers
Diltiazem 90 mg No Yes TTDE 23 Angina [, CFR [ Zhang et al., 2014 (50)
Lidoﬂazine 240–360 mg No Yes Thermodilution 11 Angina4, MBF [,
Arrhythmias*
Cannon et al., 1990 (48)
Verapamil 80 mg 4 daily No Yes Thermodilution 17 Angina [ Cannon et al., 1985 (47)
Nifedipine 10 mg 4 daily No Yes Thermodilution 9 Angina [ Cannon et al., 1985 (47)
Alpha-blockers
Doxazosin 2 mg No Yes PET scan 11 Angina4, CBF4, Rosen et al., 1999 (61)
Antianginal agents and nitrates
Ivabradine 5 mg Yes Yes TTDE 16 Angina [, CFR4 Villano et al., 2013 (68)
Isosorbide dinitrate 5 mg (SL) NA Yes TTDE 29 Stress testing4 Russo et al., 2013 (69)
Ranolazine 500–1,000 mg No Yes CMR 20 Angina [, CFR4 Mehta et al., 2011 (67)
Isosorbide dinitrate 10 mg (SL), 2 mg (IV) NA Yes Thermodilution 11 Angina Y, CBF Y Bugiardini et al., 1993 (70)
Estrogens
17b-estradiol 1 mg þ drospirenone 2 mg No NA PET 27 MPR [ Knuuti et al., 2007 (63)
Devices
EECP Yes Yes TTDE 24 Angina [, CFR [ Luo et al., 2012 (65)
TENS NA Yes IC Doppler 13 CBF Y Sanderson et al., 1996 (66)
Other
Bariatric surgery Yes NA TTDE 50 CBF [ Nerla et al., 2012 (72)
Cognac No NA TTDE 18 CFR4 Kiviniemi et al., 2008 (77)
Vitamin C 3 g infusion No N/A PET 19 CFR [ in asymptomatic
smokers
Kaufmann et al., 2000 (78)
Exercise training No No PET 13 CFR [ Czernin et al., 1995 (71)
Studies of therapies in patients who did not meet strict inclusion criteria nor had evidence of structural heart disease, heart failure, or untreated HTN, but which did assess coronary microvascular function.
[ ¼ improved with therapy;4 ¼ not statistically different; Y ¼ worse with therapy. *Treatment intervention associated with increased risk of arrhythmias.
CBF ¼ coronary blood ﬂow; CFR ¼ coronary ﬂow reserve; EECP ¼ enhanced external counterpulsation; IV ¼ intravenous; MBF ¼ myocardial blood ﬂow; N/A ¼ not assessed; SL ¼ sublingual;
TTDE ¼ transthoracic Doppler echocardiography.
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214correlation of MPR between CMR and PET. However,
the absolute measures of rest and stress ﬂow have
not correlated well. Presumably, inconsistencies
in quantiﬁcation affect rest and stress equally and
cancel out.
This systematic review excluded studies using
transthoracic Doppler echocardiography as a method
for assessing CMD. Myocardial contrast echocardiog-
raphy suffers from excessive variability (35). Doppler
echocardiography has gained some acceptance in thepublished data (36) as well as reproducibility in pop-
ulations with known CAD (37). However, this tech-
nique also suffers from variability in patient anatomy
and the inability to evaluate multiple coronary
vascular territories. Other methods not speciﬁc to the
coronary microvasculature, such as single photon
emission computed tomography perfusion imaging
and brachial artery ﬂow reserve, were excluded. We
have also excluded studies that induced hyperemia
by rapid atrial pacing.
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215SYSTEMATIC REVIEW
We performed a Medline search using Ovid, last
accessed in November 2014, to identify papers per-
taining to the treatment of CMD (Figure 2). We used
the multipurpose ﬁeld search for the terms “micro-
vascular angina,” “microvascular,” “syndrome X,”
“perfusion reserve,” “microcirculation,” “ﬂow
reserve,” or “normal coronary.” We excluded papers
not pertaining to the exploded subject headings
“heart disease” and “therapeutics and drugs (non-
mesh) or therapeutics.” We also limited our search to
humans and the English language.
As “microvascular angina” was not added as a
MeSH search term until 2005, and given the lack of
standardized nomenclature referring to CMD, a more
precise search strategy risked excluding relevant pa-
pers. We thus used a broad search strategy to yield a
relatively large number of papers (n ¼ 8,635). Single
investigator review of title and abstract was then
used to identify papers pertaining to the treatment of
chest pain without obstructive CAD. This process
identiﬁed 194 papers. Bibliographic review identiﬁed
an additional 17 papers for inclusion. A detailed re-
view by 2 independent investigators was performed
on these 211 identiﬁed papers.
A rigorous deﬁnition of CMD was established using
the following inclusion criteria: 1) human subjects; 2)
evidence of CMD, as deﬁned by a CFR or MPR <2.5
using PET, CMR, IC Doppler wire, or thermodilution
methods; and 3) angina or symptom equivalent.
We excluded papers based on the following exclusion
criteria: 1) epicardial CAD with stenosis $50% or no
evaluation of CAD (38,39); and 2) known structural
heart disease or heart failure. No statistical meta-
analytic techniques could be performed due to the
signiﬁcant heterogeneity in treatment modalities and
endpoints studied.
Of the 211 papers that underwent 2-investigator
review, 71 were excluded because they did not eval-
uate treatment. Additional exclusions from the
remaining 140 papers are detailed in Figure 2. Only 8
papers, evaluating 84 patients, met strict inclusion
criteria. Basic elements of the design and ﬁndings of
these analyses are provided in Table 1. They represent
6% of the 139 studies on the treatment of CMD. The
mean number of subjects per study was 10  4. These
studies evaluated pravastatin, sildenaﬁl, quinapril,
intravenous L-arginine, intravenous diltiazem, dox-
azosin, estrogen, and transcutaneous electrical nerve
stimulation application in the treatment of CMD.
Their endpoints encompassed different domains,
including symptomatology, exercise capacity,
markers of ischemia, and coronary blood ﬂow (CBF).The studies evaluating sildenaﬁl, quinapril, enalapril,
estrogens, and transcutaneous electrical nerve stim-
ulation application demonstrated beneﬁts in their
respective endpoints. No beneﬁt was found with
L-arginine, doxazosin, pravastatin, and diltiazem.
MICROVASCULAR ANGINA
TREATMENT OPTIONS
This systematic review identiﬁed little evidence
evaluating treatment strategies in patients with
likely CMD. However, there are many analyses across
multiple treatment modalities that have tangentially
addressed this question and can inform future
research design. The studies meeting inclusion
criteria will be described in the following text. We will
also discuss other studies that examined microvas-
cular function in patients with chest pain but did not
meet inclusion criteria. These studies have been
summarized in Table 2. We have opted not to discuss
studies pertaining to patients with structural heart
disease, heart failure, or untreated hypertension.
Although there are numerous other studies that have
addressed therapies for CMD in other clinical settings,
such as idiopathic dilated cardiomyopathy, hyper-
trophic obstructive cardiomyopathy, and Takotsubo
cardiomyopathy, these studies were beyond the
scope of this analysis.
THERAPEUTICS WITH STUDIES MEETING
INCLUSION CRITERIA
RENIN-ANGIOTENSIN-ALDOSTERONE PATHWAY
INHIBITION. It is well established that angiotensin II
is a potent coronary vasoconstrictor. It has been
proposed that angiotensin-converting enzyme
inhibitors may directly modulate coronary micro-
vascular tone (40). There was 1 study using
angiotensin-converting enzyme inhibitors that met
strict inclusion criteria. Pauly et al. (41) conducted a
double-blind placebo-controlled trial of quinapril in
13 women with chest pain without obstructive CAD
and with reduced CFR (#2.5). They found signiﬁcant
changes in CFR with therapy (þ0.55  0.50)
measured by IC Doppler (41). Two other studies by
Kaski et al. (42) and Motz et al. (43), which were
excluded from the systematic review, showed
improved stress test parameters and, in the latter
study, improved CFR. Bavry et al. (44) found no
signiﬁcant improvement in adding eplerenone to
angiotensin II inhibition (44).
CALCIUM-CHANNEL BLOCKERS. Calcium-channel
blockers have been shown to decrease microvas-
cular tone and relieve spasm, thereby potentially
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216improving CFR or MPR in patients with CMD (45).
Only 1 study met our strict inclusion criteria. Sutsch
et al. (46) performed a case-controlled study of 16
patients to evaluate the effect of diltiazem on CBF.
Five minutes after administration of intravenous
diltiazem, there was a nonsigniﬁcant decrease in CBF
from 178 to 170 ml/min in patients with microvascular
angina. The study concluded that diltiazem failed to
correct the impaired CFR (46). Verapamil, nifedipine,
and lidoﬂazine have been shown to improve exercise
stress test parameters, and lidoﬂazine has been
shown to reduce coronary resistance but was associ-
ated with fatal arrhythmias (47,48). Multiple other
studies have evaluated the role of calcium-channel
blockers in patients with left ventricular hypertro-
phy or untreated hypertension. These patients were
excluded.
STATINS. Statins may improve CMD through anti-
inﬂammatory and antiatherosclerotic effects. A total
of 10 studies have evaluated the role of statins in
patients with chest pain without obstructive CAD.
Only 1 study by Houghton et al. (49) met our in-
clusion criteria. This study evaluated pravastatin
in 6 patients with an average baseline CFR of
0.97  0.13. After 6 months of therapy, the CFR had
increased to 1.60  0.16 with administration of
acetylcholine. However, there was no assessment of
nonendothelial-dependent dilation or of symptoms
of chest pain (49).
Zhang et al. (50) showed improvement in CFR and
symptoms with ﬂuvastatin, and Eshtehardi et al. (51)
and Caliskan et al. (52) demonstrated CFR improve-
ment in patients treated with atorvastatin; however,
this was only signiﬁcant in the study by Caliskan et al.
(52). To further support the role of lipid-lowering
therapies in the treatment of CMD, Nemes et al. (53)
has shown that an inability to achieve cholesterol
response on statin therapy is associated with worse
CFR.
NITRIC OXIDE MODULATORS. Nitric oxide (NO) is a
key player in endothelium-dependent mediation of
coronary microvasculature tone through the activa-
tion of a guanylate cyclase signaling pathway pre-
venting smooth muscle activation (54). Sildenaﬁl
works to inhibit the breakdown of cyclic guanosine
monophosphate and, thus, promotes vascular smooth
muscle relaxation. One study compared the role of a
1-time dose of sildenaﬁl in symptomatic patients with
CFR #2.5 or >2.5. Those patients with reduced CFR
showed an increase in CFR from 2.1  0.2 to 2.7  0.6
(p ¼ 0.006). There was no signiﬁcant difference in
CFR measurements in patients with CFR >2.5. The
effect on symptoms was not evaluated (55).L-arginine is a precursor of NO, and thus, its sup-
plementation may improve microvascular function.
One study evaluating L-arginine met our inclusion
criteria. Bøttcher et al. (56) tested a 1-time infusion of
L-arginine in 25 patients with chest pain without
obstructive CAD and with CMD on PET. They noted no
improvement in symptoms after infusion (56).
Egashira et al. (57) and Gellman et al. (58) noticed
improvement in CBF after a single infusion of
L-arginine, whereas Lerman et al. (59) found
improvement in symptoms but no change in CFR af-
ter 6 months of supplementation.
ALPHA-BLOCKERS. Alpha-blockers decrease sympa-
thetic activity and, thus, potentially decrease micro-
vascular tone and improve microvascular perfusion.
One study met inclusion criteria. In a double-blind,
placebo-controlled, crossover study of 16 patients
with microvascular angina given doxazosin daily for
10 weeks, Bøtker et al. (60) found no difference in
exercise duration, time to angina pectoris, and exer-
cise time to $0.1 mV ST-segment depression when
compared with placebo. Rosen et al. (61) also showed
no improvement in MBF or CFR.
ESTROGENS. Given the prevalence of chest pain
without obstructive CAD in post-menopausal women,
it has been theorized that an estrogen deﬁciency may
play a role in CMD. One study by Bairey Merz et al.
(62) met our inclusion criteria. This study showed an
improvement in anginal symptoms but no improve-
ments in myocardial ischemia or brachial artery
ﬂow-mediated dilation. Another study by Knuuti
et al. (63) demonstrated improved average MPR after
estrogen use.
SPINAL CORD STIMULATORS AND OTHER DEVICES.
Spinal cord stimulators and enhanced external
counterpulsation (EECP) have been examined in pa-
tients with chest pain without obstructive CAD. Spi-
nal stimulation is believed to modulate pain-related
nerve signals and increase MBF through effects on
sympathetic tone. EECP increases diastolic blood
ﬂow to the heart. A single study by Jessurun et al.
(64) met our inclusion criteria and found an
improvement in symptoms after the use of trans-
cutaneous spinal cord stimulator therapy. Their pa-
tients went from reporting 20  3 chest pain
episodes/week to reporting 3  1 episodes/week
(p ¼ 0.012). There was also an improvement in
MPR. Luo et al. (65) also found improvement in both
CFR and angina symptoms in patients treated with
EECP. Sanderson et al. (66), in contrast, found no
improvement with transcutaneous electric nerve
stimulators.
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217THERAPEUTICS WITHOUT STUDIES MEETING
INCLUSION CRITERIA
BETA-BLOCKERS. Beta-blockers reduce myocardial
oxygen demand and increase diastolic perfusion
time; thus, they have a compelling potential role in
the treatment of CMD. They were the most-studied
intervention. Despite this, no studies met our strict
inclusion criteria. Multiple studies evaluated the role
of beta-blockers in the treatment of CMD in patients
with nonischemic dilated cardiomyopathy and were
excluded.
ANTIANGINALS AND NITRATES. Multiple drugs that
reduce angina have been studied in chest pain
without obstructive CAD, including ivabradine,
ranolazine, mibefradil, nicorandil, and trimetazidine.
However, no studies met our strict inclusion criteria.
These agents use numerous different mechanisms,
although most work to reduce myocardial oxygen
demand and, thus, reduce ischemia. Of these in-
terventions, ranolazine was best studied. Mehta et al.
(67) found an improved MPR in the subgroup of pa-
tients with baseline CFR <3. Villano et al. (68) found
improvements in various symptomatic and stress test
metrics, but no improvement in MBF.
Nitrates increase smooth muscle relaxation and,
therefore, produce a vasodilator effect on veins and
arteries (54). Several studies have examined the role of
nitrates in chest pain without obstructive CAD and
have found no beneﬁt. Russo et al. (69) showed no
signiﬁcant change in stress test parameters after use of
isosorbide dinitrate. Bugiardini et al. (70) observed
worse angina and reduced CBFwith rapid atrial pacing.
OTHER THERAPIES. Adenosine receptor blockade
with members of the xanthine family, such as
theophylline, were assessed in 6 small studies, none
of which assessed MVD. These studies had mixed
results. However, the majority reported improved
exercise capacity.
Nine studies have evaluated psychiatric pharma-
cological interventions, including tricyclic antide-
pressants such as imipramine as well as various
relaxation and psychiatric interventions. Although
many showed an improvement in symptoms, none of
these studies evaluated microvascular dysfunction,
resulting in a heterogeneous treatment population
with limited applicability to CMD.
Czernin et al. (71) studied 6 weeks of aerobic ex-
ercise training versus a low cholesterol diet and
relaxation techniques; they found an improvement in
CFR in the exercise group. Nerla et al. (72) evaluated
bariatric surgery and also found improvements in
CBF; however, this was in patients without CMD.Multiple other treatments have been evaluated,
including metformin, vitamin C, anticoagulants,
cognac, and traditional Chinese medical techniques.
However, none of these studies limited their pop-
ulations to patients with likely CMD.
NEXT STEPS IN CMD RESEARCH
Given its unique pathophysiology and prognosis, it is
important that microvascular angina be studied
independently of other causes of chest pain without
obstructive CAD, such as cardiac syndrome X, coro-
nary spasm, and noncardiac causes of chest pain. Our
review highlights the lack of evidence evaluating
therapies to relieve angina and reduce risk in this
morbid population. We propose a blueprint to pro-
mote more consistency in deﬁning research pop-
ulations for future treatment studies.
The ﬁrst necessary step is to develop a universal
deﬁnition of CMD. Variations in blood ﬂow esti-
mates due to the imaging modality, stress agent,
and quantiﬁcation method are partially abated
by the use of CFR or MPR. However, differences
remain, and these parameters affect the relation-
ship between CFR or MPR and clinical endpoints
such as mortality (27). Further research to precisely
identify the optimal cut point for the diagnosis of
pathologic CMD across varying patient populations
and estimation methods will be essential. Stan-
dardized protocols will allow for reﬁned estimates
of prognosis and the development of optimal
therapies.
In the interim, we propose a 3-tiered character-
ization of the likelihood of CMD based on the avail-
able prognostic data. Multiple studies examining
prognosis in CMD have demonstrated that there are
increased events in patients with reduced CFR or
MPR, using disparate cutoffs ranging from 1.5 to 2.5.
Murthy et al. (8) demonstrated a 5.6-fold increased
risk of cardiac death in patients with suspected CAD
and CFR <1.5. Thus, it seems likely that patients with
a CFR <1.5 have CMD. Multiple other studies have
used cutoffs that ranged from 1.5 to 2.5 to identify
cohorts at increased risk due to presumed CMD.
Therefore, it is likely that patients with a CFR or MPR
>2.5 are unlikely to have CMD, and an alternative
pathophysiologic mechanism for chest pain should
be pursued. Those with a CFR or MPR between 1.5
and 2.5 fall in an indeterminate range and may
have CMD. In patients without obstructive CAD
(Pepine et al. [2]) and with CAD (Fukushima
et al. [11]), cutoffs of 2.32 and 2.11, respectively,
identiﬁed CMD. Other studies have used 2.0 as their
cutoff (10,73). Suwaidi et al. (22) used a cutoff
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for endothelial-independent dilation in patients
without obstructive CAD.
The second necessary step is a transition to the
routine assessment of CMD using validated imaging
techniques in patients with chest pain without
obstructive CAD. Deﬁnitive diagnosis of microvas-
cular angina allows for validation of patient symp-
toms, differentiation from other clinical syndromes
with potentially different therapeutic and prognostic
implications, and initiation of more aggressive risk
factor reduction (if a beneﬁt is conﬁrmed by future
research).
The third step is to assess for effective therapies
speciﬁcally in patients with microvascular angina.
Future research should assess for improvements in
symptoms, quality of life, and prognosis using both
drug classes effective in microvascular angina and
therapies that exploit the unique pathophysiology
of CMD. Commonly used antianginal therapies, such
as beta-blockers, calcium-channel blockers, nitrates,
and statins, have not been adequately examined in
the CMD population. Novel approaches could include
treatment of metabolic syndrome and intensive
exercise.
CONCLUSIONS
Chest pain without obstructive CAD is a heteroge-
neous entity in which a subset of patients experi-
ences microvascular angina. In contrast to the
favorable prognosis of most patients with chest pain
without obstructive CAD, the presence of CMD is
associated with poor outcomes. However, there is no
standardized approach to deﬁning CMD. The lack of
standardized deﬁnitions has made the evaluation of
treatment strategies for microvascular angina chal-
lenging. Only recently have advancements in PET
and CMR allowed for widespread evaluation ofmicrovascular function in patients with chest pain
without obstructive CAD. However, even with these
advances, the optimal strategy for diagnosing CMD is
not clear.
After reviewing the published data, we found that
there is little evidence to support current treatment
strategies for objectively-deﬁned CMD. Current
practice is to use traditional antianginal and risk-
reduction therapies targeted at epicardial CAD.
However, these may not be effective in the manage-
ment of CMD, as exempliﬁed by the paradoxical ef-
fects seen in the data exploring the use of nitrates in
chest pain without obstructive CAD.
Both prognostic and treatment studies suggest that
those patients with the lowest CFR or MPR values
have the worse prognosis. This group also seems to
derive the most beneﬁt from therapy. This suggests
that CFR and MPR are important clinical indicators of
physiologic dysfunction and should be used to guide
therapy.
There is still considerable work needed to deﬁni-
tively address optimal therapy for CMD. After com-
mon deﬁnitions are adopted and CMD is routinely
assessed in patients with chest pain without
obstructive CAD, traditional and novel treatment
strategies can be assessed to reduce symptoms,
improve quality of life, and reduce risk in this prev-
alent and morbid disease.
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